Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer
Clinical trial NCT04448379 · UNKNOWN
Trial details
- NCT number
- NCT04448379
- Sponsor
- Shanghai JMT-Bio Inc.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-06-29
- Primary completion
- 2021-12-31
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.